Cargando…

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine

BACKGROUND: Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins. METHODS: In a phase 2a randomized double-blind, placebo-controlled trial, healthy participants aged 18 to 50 y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jordan, Elke, Kabir, Golam, Schultz, Stephanie, Silbernagl, Günter, Schmidt, Darja, Jenkins, Victoria A, Weidenthaler, Heinz, Stroukova, Daria, Martin, Barbara K, De Moerlooze, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582911/ https://www.ncbi.nlm.nih.gov/pubmed/37079393 http://dx.doi.org/10.1093/infdis/jiad108

Ejemplares similares

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
por: Weidenthaler, Heinz, et al.
Publicado: (2022)

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
por: Ilchmann, Heiko, et al.
Publicado: (2022)

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
por: Maclennan, Jane, et al.
Publicado: (2019)

A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
por: Turner Overton, Edgar, et al.
Publicado: (2023)

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children( )
por: Ishola, D
Publicado: (2022)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
por: Koivisto, Karoliina, et al.
Publicado: (2021)

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years
por: Del Riccio, Marco, et al.
Publicado: (2023)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children
por: Karron, Ruth A, et al.
Publicado: (2020)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
por: Jenkins, Victoria A., et al.
Publicado: (2023)

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
por: Green, C A, et al.
Publicado: (2015)

Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine
por: Matusali, Giulia, et al.
Publicado: (2023)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice
por: Roe, Molly K, et al.
Publicado: (2022)

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
por: Endt, Kathrin, et al.
Publicado: (2022)

The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries
por: Staadegaard, Lisa, et al.
Publicado: (2021)

Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus †
por: Joshi, Sameer, et al.
Publicado: (2018)

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
por: Zaeck, Luca M., et al.
Publicado: (2022)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Modeling household dynamics on Respiratory Syncytial Virus (RSV)
por: Mahikul, Wiriya, et al.
Publicado: (2019)

Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
por: Murray, Jackelyn, et al.
Publicado: (2022)

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
por: Gatt, Dvir, et al.
Publicado: (2023)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
por: McLaughlin, John M, et al.
Publicado: (2022)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
por: Overton, Edgar Turner, et al.
Publicado: (2018)

Transmission of Respiratory Syncytial Virus Infection Within Families
por: Heikkinen, Terho, et al.
Publicado: (2014)

Influenza A and Respiratory Syncytial Virus Trigger a Cellular Response That Blocks Severe Acute Respiratory Syndrome Virus 2 Infection in the Respiratory Tract
por: Dee, Kieran, et al.
Publicado: (2022)

Epidemiological Changes of Respiratory Syncytial Virus (RSV) Infections in Israel
por: Hirsh, Shira, et al.
Publicado: (2014)

Strategic priorities for respiratory syncytial virus (RSV) vaccine development
por: Anderson, L.J., et al.
Publicado: (2013)

Perinatal Lamb Model of Respiratory Syncytial Virus (RSV) Infection
por: Derscheid, Rachel J., et al.
Publicado: (2012)

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vhe5q6jbjb6eq2l7d76bdbfqd